Uveal melanoma therapy on the horizon?

No authors listed

Comment

No authors listed. Cancer Discov. 2014 Sep.

. 2014 Sep;4(9):OF6.

doi: 10.1158/2159-8290.CD-NB2014-103. Epub 2014 Jul 9.

Abstract

A phase II trial of the MEK inhibitor selumetinib offers hope for patients with metastatic uveal melanoma, a rare and fatal eye cancer.

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK. Carvajal RD, et al. JAMA. 2014 Jun 18;311(23):2397-405. doi: 10.1001/jama.2014.6096. JAMA. 2014. PMID: 24938562 Free PMC article. Clinical Trial.